Start / PharmaTalkRadio / Alzheimers studies exploring registries to improve enrollment trial design

Alzheimer’s Studies: Exploring Registries to Improve Enrollment & Trial Design

29 min • 25 juni 2019

Roughly, 5.7 million people in the U.S. are living with Alzheimer’s. Globally, an estimated 47 million individuals are living with dementia. There is no cure, and treatments can only relieve certain symptoms for some people. Research studies so far have a poor record. Patients can face incredible enrollment hurdles in clinical trials. A Patient Registry can be very useful in identifying patients. A registry can also address the original problem statement about failed trials. A robust, living registry becomes a data pool from which we can improve both drug discovery, using probabilistic statistics and AI/ML to identify new drug candidates, and drug development, using simulators to predict likelihood of success in Phase 2 or 3. In this podcast, we discuss major challenges facing developers of Alzheimer’s therapies and address patient registries and how they can improve enrollment and trial design. In this podcast, we will hear some details about the HealthyMindsRegistry, Synexushmr.com and the Protect Study Registry, Protectstudy.org.uk registry. For US and UK citizens over 50 who have not been diagnosed with dementia can participate in the registry on-line. Guests: Dr Clive Ballard, Pro-Vice Chancellor and Executive Dean, University of Exeter, External partner in the AES HealthyMinds Registry (HMR) Dr Heather Bryson, Director, Operational and Strategic Solutions at Accelerated Enrollment Solutions, (AES) Host: Dr Julie Adams, Psychiatrist and Regional Medical Officer, PPD Biotech Producer: Valerie Bowling, Executive Director, the Conference Forum

Senaste avsnitt

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Alzheimer’s Studies: Exploring Registries to Improve Enrollment & Trial Design

Senaste avsnitt

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

Directors' Talk DPHARM 2025 - AI Sessions; Part III

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

Catalyzing Change: The Business Imperative of Patient-Centric Drug Development

How Emerging Biopharma CMOs Can Better Partner with Patient Organizations

Joint Site and Sponsor Perspectives on Innovative Solutions Addressing Sites Challenges

What to Expect at the CRAACO: Clinical Research as a Care Option 2025 Event

Directors' Talk PODD 2025 - Keynotes & Key Themes

Enhanced Strategic FDA Collaboration: Working with CDER and CBER

Biomaterial Implants to Reduce Patient Burden and Improve Adherence

Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?

2025 Biotech Markets & Immuno-Oncology Outlook

Directors' Talk DPHARM 2025 - Pharma from the Trenches; Part II

Directors' Talk DPHARM 2025 - Keynotes & Key Topics; Part I

Streamlining Effective Patient Engagement through Pharma-Patient Advocacy Collaboration

Lessons Learned in the Development and Introduction of Closed Loop Systems

Best Practices and Potential Pitfalls Enriching Clinical Trials with PROs

Operationalizing the Patient Voice for Long-Term Protocol Planning and Execution

Navigating Data Quality and Scalability Challenges when Using Real-World Data from EHRs

Addressing the Realities of Scaling T-Cell Therapies for Patient Access and Affordability

The Current Status of Patient Centricity in Medicine Development

Patients as Partners Caregiver Keynote - The Life-Changing Power of a Clinical Trial

Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape

Sustained Release Innovations to Reduce Patient Burden

How Pharma Is Adopting Generative AI Across Clinical Development

Tufts Center for Study of Drug Development on Evolving Clinical Trial Partnerships

New Approaches to Achieve Targeted Brain Delivery Without Increasing Toxicity

Partnering with Patients in Clinical Development Using the Biopsychosocial Model

Vaccine Delivery Innovations

How PALADIN Consortium Aims to Enhance Efficient Patient Advocacy-Industry Collaborations

What CMOs Need to Know and Do When Preparing for Product Launch

What to Expect at the 2025 Patients as Partners EU Conference

Understanding Financial Barriers to Getting More Coverage for Patients in Clinical Trials

How Montefiore Gets Early Stage Clinical Trials to Under-Resourced Communities

Investment Trends in Immuno-Oncology

Advances in Pulmonary Delivery of Biologics

Strategies for CMOs to Scale Up Effectively as Their Biotech Company Evolves

Boehringer Ingelheim on Collaborations in Clinical Development for Launch Readiness

Payer Perspectives on Drug Delivery

Patient Engagement: Practical Approaches for Emerging Biotech CMOs

Immuno-Oncology Debate 2024 on Solving Cancer’s Top Challenges

CMO Misunderstandings about Clinical Operations and How to Improve

How Roche is Maximizing the Impact of Patient Insights in Early Development

Designing and Developing Drug Delivery for Lower and Middle-Income Countries

Making Clinical Research a Feasible Care Option Using Modern Software Infrastructure

Innovative Approach for Elevating Patient-Centric Solutions in Pediatric Trials

Using Patient Insights Meaningfully throughout the Medicine & Disease Lifecycle

Incorporating Quantitative Values of Patient Perspectives into Trial Design

Accessing a Novel Source of Patient Experience Data to Improve Clinical Research

Empathy and Behavioral Science in ePROs to Increase Data Collection Adherence

Antiviral Drug Development: Overcoming Challenges to the Current Model

Strategies to Empower Clinical Sites, Streamline Trials and Enhance Patient Care

Unlocking Pre-Enrollment Data to Help Sponsors Recruit and Enroll More Patients

The History of Tumor Vaccines, and Why the Newest RNA Cancer Vaccines Might Work

What Biotech CEOs Need to Know about Developing a Commercialization Roadmap

Simplicity in Technology Delivery for Clinical Trials

Micromachines, Biologic Approaches and New Tools Pushing the Boundaries in Oral

Combining AI and Empirical Science to Advance Cancer Immunotherapies

The Personal Impact of a Clinical Trial

The Future of Patient-Centricity: Advancing Frameworks to Achieve Greater Impact

Using AI to Accelerate the Next Generation of Oncology Immunotherapies

Immuno-Oncology Cell Therapy Data Analytics: What and How to Measure

What to Expect at CRAACO: Clinical Research as a Care Option 2024, in 5 Minutes

How to Enhance Clinical Trial Participation in Diverse Linguistic Backgrounds

Patient Engagement Advocate on Collaborating Successfully with Pharma

What to Expect at DPHARM 2024, with DPHARM Directors

Astellas Head of Patient Centricity on Patient-Centric Medicine Development

Preferences in Decentralization and Digitalization of Pediatric Clinical Trials

How CMOs Build a Network of Consultants

What CMOs Need to Know about Partnering with Hospitals & Clinical Research Sites

Transitioning from Early Stage to Registrational/Pivotal Stage Development

CMO Insights and Advice on Tailoring Your Pitch to Investors

Discoveries from the Clinic that Help Inform IO Cell Therapy Moving Forward

Using Sustainability to Empower Patient Engagement Goals in Medicine Development

The CMO as a Translational Scientist

Maximizing Regulatory Interactions